STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are \u201cclinical, financial, and regulatory considerations\u201d that must be reviewed before it will take that step.<\/p>\n
Not surprisingly, though, what the largest pharmacy benefits manager in the U.S. simply wants is a much lower price, according to email sent this week by a company executive to an AIDS patient advocacy group.<\/p>\n
At issue is Yeztugo, a groundbreaking medicine that was approved last June<\/a> by the U.S. Food and Drug Administration. Clinical trials showed the twice-a-year injectable was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the $28,000 price tag in the U.S. has raised concern about affordability.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n